Ben M'barek Lilia, Mebazaa Amel, Euvrard Sylvie, Frances Camille, Thervet Eric, Morel Patrice, Menasché Suzanne, Legendre Christophe, Lebbe Celeste
Department of Dermatology, Saint-Louis Hospital, Paris, France.
Dermatology. 2007;215(2):130-3. doi: 10.1159/000104264.
Topical imiquimod is a new immunomodulator agent approved for genital warts, actinic keratosis (AK) or carcinoma, occurring in immunocompetent patients.
This study aimed to assess the safety and efficacy of imiquimod for the treatment of warts, AK and bowenoid papulosis (BP) in transplant patients.
24 transplant patients (18 kidney, 4 kidney-pancreas and 2 heart) were included in this retrospective study conducted between June 2000 and February 2003 at the department of dermatology of 3 hospitals. Imiquimod cream was applied 3 times a week over a median period of 9 weeks.
Graft function was not altered under therapy. Local tolerance was excellent. Complete responses were observed in 1 patient (1/12) with cutaneous warts and 1 (1/6) with AK. Two patients of 3 with BP had total clearance of their lesions. Partial responses were observed in 3 of the 6 AK-treated patients, 5 of 12 patients with cutaneous warts and 1 of 2 patients with anogenital warts.
Imiquimod 5% cream is a promising, well-tolerated therapy for warts, AK and BP in transplant recipients.
局部用咪喹莫特是一种新的免疫调节剂，已被批准用于治疗免疫功能正常患者的尖锐湿疣、光化性角化病（AK）或癌。
本研究旨在评估咪喹莫特治疗移植患者疣、AK和鲍温样丘疹病（BP）的安全性和疗效。
2000年6月至2003年2月期间，在3家医院皮肤科进行的这项回顾性研究纳入了24例移植患者（18例肾移植、4例肾胰联合移植和2例心脏移植）。咪喹莫特乳膏每周应用3次，中位疗程为9周。
治疗期间移植功能未改变。局部耐受性良好。1例（1/12）皮肤疣患者和1例（1/6）AK患者观察到完全缓解。3例BP患者中有2例皮损完全清除。6例接受AK治疗的患者中有3例、12例皮肤疣患者中有5例以及2例肛门生殖器疣患者中有1例观察到部分缓解。
5%咪喹莫特乳膏是治疗移植受者疣、AK和BP的一种有前景且耐受性良好的疗法。
